Mildronate effects on cognitive function in elderly patients with arterial hypertension
Aim. To assess the effects of the “interval” (3 months of treatment, followed by treatment-free 3 months) and “persistent” (52 weeks) therapy with Mildronate (500 mg/d) in elderly patients with arterial hypertension (AH) and cognitive dysfunction. Material and methods. In total, 1800 elderly patient...
Saved in:
| Main Authors: | S. V. Nedogoda, M. E. Statsenko, S. V. Turkina, I. A. Tyshchenko, L. V. Poletaeva, V. V. Tsoma, A. A. Ledyaeva, E. N. Chumachok, O. L. Bykova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2012-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1911 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MILDRONATE POTENTIAL FOR CORRECTING COGNITIVE DYSFUNCTION IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION
by: M. E. Statsenko, et al.
Published: (2011-08-01) -
ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM
by: M. E. Statsenko, et al.
Published: (2015-09-01) -
EFFECTS OF MILDRONATE, AS A PART OF COMBINED HEART FAILURE THERAPY, ON CARBOHYDRATE AND LIPID METABOLISM AND OXIDATIVE STRESS PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2010-04-01) -
MILDRONATE THERAPY IN PATIENTS WITH CHRONIC HEART FAILURE, TYPE 2 DIABETES MELLITUS AND AUTONOMOUS CARDIAC NEUROPATHY
by: M. E. Statsenko, et al.
Published: (2009-06-01) -
Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives
by: V. P. Mikhin, et al.
Published: (2012-02-01)